Overview

Oncology Drugs Market is poised to value over CAGR of over 11.4% during the forecast period 2022 to 2028

FutureWise Market Research has instantiated a report that provides an intricate analysis of Oncology Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Oncology Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Oncology Drugs Market:
• F. Hoffmann-La Roche Ltd (Basel, Switzerland)
• Genentech, Inc. (California, United States)
• Novartis AG (Basel, Switzerland)
• Pfizer Inc. (New York, United States)
• Bristol-Myers Squibb Company (New York, United States)
• GlaxoSmithKline plc. (Brentford, United Kingdom)
• Eli Lilly and Company (Indiana, United States)
• AstraZeneca (Cambridge, United Kingdom)
• Sanofi (Paris, France)
• Bayer AG (Leverkusen, Germany)
• Celgene Corporation
• Merck & Co., Inc.
• Johnson & Johnson (Janssen Global Services, Llc,)
• AbbVie Inc.
• Astellas Pharma Inc.
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Oncology Drugs Market Segmentation:
By Drug Class
• Cytotoxic Drugs
 o Alkylating Agents
 o Antimetabolites
 o Others
• Targeted Drugs
 o Monoclonal Antibodies
 o Others
• Hormonal Drugs
• Others

By Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Indication
• Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Others

By Dosage Form
• Solid
 o Tablets
 o Capsules
• Liquid
• Injectable
 o Prefilled Syringes
 o Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Oncology Drugs Market By Drug Class, By Therapy, By Indication, By Dosage Form,  By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Oncology Drugs Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Oncology Drugs Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Oncology Drugs Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Oncology Drugs Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Cytotoxic Drugs
       7.1.1. Alkylating Agents
       7.1.2. Antimetabolites
       7.1.3. Others
  7.2. Targeted Drugs
       7.2.1. Monoclonal Antibodies
       7.2.2. Others
  7.3. Hormonal Drugs
  7.4. Others

8. Global Oncology Drugs Market, By Therapy Historical Analysis and Forecast 2022-2028 (USD Million)
  8.1. Chemotherapy
  8.2. Targeted Therapy
  8.3. Immunotherapy

9. Global Oncology Drugs Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million)
  9.1. Lung Cancer
  9.2. Stomach Cancer
  9.3. Colorectal Cancer
  9.4. Breast Cancer
  9.5. Prostate Cancer
  9.6. Others

10. Global Oncology Drugs Market, by Dosage Form Historical Analysis and Forecast 2022-2028 (USD Million)
  10.1. Solid
        10.1.1. Tablets
        10.1.2. Capsules
  10.2. Liquid
  10.3. Injectable
        10.3.1. Prefilled Syringes
        10.3.2. Others

11. Global Oncology Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)
  11.1. Hospital Pharmacies
  11.2. Retail Pharmacies
  11.3. Online Pharmacies
  11.4. Others

12. North America Oncology Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  12.1. Introduction
  12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       12.2.1. U.S.A
       12.2.2. Canada
       12.2.3. Mexico
  12.3. Market Size (USD Million) Forecast for North America 2022-2028

13. Latin America Oncology Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. Brazil
         13.2.2. Venezuela
         13.2.3. Argentina
         13.2.4. Rest of Latin America
   13.3. Market Size (USD Million) Forecast for Latin America 2022-2028

14. Europe Oncology Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         14.2.1. Germany
         14.2.2. U.K        
         14.2.3. France
         14.2.4. Italy
         14.2.5. Spain
         14.2.6. Russia
         14.2.7. Poland
         14.2.8. Rest of Europe
   14.3. Market Size (USD Million) Forecast for Europe 2022-2028

15. Asia Pacific Oncology Drugs Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   15.1. Introduction
   15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         15.2.1. Japan
         15.2.2. China
         15.2.3. India
         15.2.4. Australia and New Zealand
         15.2.5. ASEAN
         15.2.6. Rest of Asia Pacific
   15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   16.1. Introduction
   16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         16.2.1. GCC
         16.2.2. Israel
         16.2.3. South Africa
         16.2.4. Rest of MEA
   16.3. Market Size (USD Million) Forecast for MEA 2022-2028

17. Market Share Analysis and Competitive Landscape  
   17.1. Global Landscape - Key Players, Revenue and Presence
   17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   17.3. Global Emerging Companies
   17.4. North America - Market Share Analysis and Key Regional Players
   17.5. Europe - Market Share Analysis and Key Regional Players
   17.6. Asia Pacific - Market Share Analysis and Key Regional Players
   17.7. Global Key Player - Growth Matrix

18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   18.1. F. Hoffmann-La Roche Ltd (Basel, Switzerland)
         18.1.1. Company Overview
         18.1.2. Product Portfolio
         18.1.3. SWOT Analysis
         18.1.4. Financial Overview
         18.1.5. Strategic Overview
   18.2. Genentech, Inc. (California, United States)
         18.2.1. Company Overview
         18.2.2. Product Portfolio
         18.2.3. SWOT Analysis
         18.2.4. Financial Overview
         18.2.5. Strategic Overview
   18.3. Novartis AG (Basel, Switzerland)
         18.3.1. Company Overview
         18.3.2. Product Portfolio
         18.3.3. SWOT Analysis
         18.3.4. Financial Overview
         18.3.5. Strategic Overview
   18.4. Pfizer Inc. (New York, United States)
         18.4.1. Company Overview
         18.4.2. Product Portfolio
         18.4.3. SWOT Analysis
         18.4.4. Financial Overview
         18.4.5. Strategic Overview
   18.5. Bristol-Myers Squibb Company (New York, United States)
         18.5.1. Company Overview
         18.5.2. Product Portfolio
         18.5.3. SWOT Analysis
         18.5.4. Financial Overview
         18.5.5. Strategic Overview          
   18.6. GlaxoSmithKline plc. (Brentford, United Kingdom)
         18.6.1. Company Overview
         18.6.2. Product Portfolio
         18.6.3. SWOT Analysis
         18.6.4. Financial Overview
         18.6.5. Strategic Overview      
   18.7. Eli Lilly and Company (Indiana, United States)
         18.7.1. Company Overview
         18.7.2. Product Portfolio
         18.7.3. SWOT Analysis
         18.7.4. Financial Overview
         18.7.5. Strategic Overview
   18.8. AstraZeneca (Cambridge, United Kingdom)
         18.8.1. Company Overview
         18.8.2. Product Portfolio
         18.8.3. SWOT Analysis
         18.8.4. Financial Overview
         18.8.5. Strategic Overview
   18.9. Sanofi (Paris, France)
         18.9.1. Company Overview
         18.9.2. Product Portfolio
         18.9.3. SWOT Analysis
         18.9.4. Financial Overview
         18.9.5. Strategic Overview
   18.10.Bayer AG (Leverkusen, Germany)
         18.10.1. Company Overview
         18.10.2. Product Portfolio
         18.10.3. SWOT Analysis
         18.10.4. Financial Overview
         18.10.5. Strategic Overview
   18.11.Celgene Corporation
         18.11.1. Company Overview
         18.11.2. Product Portfolio
         18.11.3. SWOT Analysis
         18.11.4. Financial Overview
         18.11.5. Strategic Overview
   18.12.Merck & Co., Inc.
         18.12.1. Company Overview
         18.12.2. Product Portfolio
         18.12.3. SWOT Analysis
         18.12.4. Financial Overview
         18.12.5. Strategic Overview
   18.13.Johnson & Johnson (Janssen Global Services, Llc,)
         18.13.1. Company Overview
         18.13.2. Product Portfolio
         18.13.3. SWOT Analysis
         18.13.4. Financial Overview
         18.13.5. Strategic Overview
   18.14.AbbVie Inc.
         18.14.1. Company Overview
         18.14.2. Product Portfolio
         18.14.3. SWOT Analysis
         18.14.4. Financial Overview
         18.14.5. Strategic Overview
   18.15.Astellas Pharma Inc.
         18.15.1. Company Overview
         18.15.2. Product Portfolio
         18.15.3. SWOT Analysis
         18.15.4. Financial Overview
         18.15.5. Strategic Overview                  

19. Pre and Post COVID-19 Impact
   19.1. Positive influence on the healthcare industry
   19.2. The financial disruption of the manufacturing sector
   19.3. Impact of COVID-19 on emerging companies
   19.4. Significant mandates in the healthcare regulations initiated by administrations
   19.5. The overall economic slowdown of the developing and developed nations

20. FutureWise SME Key Takeaway Points for Client

Tables

Figures